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ABSTRACT
ObjectiveToexaminetheriskofsuicidalbehaviourwithin
clinical trials of antidepressants in adults.
Design Meta-analysis of 372 double blind randomised
placebo controlled trials.
SettingDrugdevelopmentprogrammesforanyindication
in adults.
Participants 99231 adults assigned to antidepressants
or placebo. Median age was 42 and 63.1% were women.
Indicationsfortreatmentweremajordepression(45.6%),
other depression (4.6%), other psychiatric disorders
(27.6%), and non-psychiatric disorders (22.2%).
Main outcome measures Suicidal behaviour (completed
suicide, attempted suicide, or preparatory acts) and
ideation.
Results For participants with non-psychiatric indications,
suicidal behaviour and ideation were extremely rare. For
those with psychiatric indications, risk was associated
with age. For suicidal behaviour or ideation and for
suicidal behaviour only, the respective odds ratios were
1.62 (95% confidence interval 0.97 to 2.71) and 2.30
(1.04 to 5.09) for participants aged <25, 0.79 (0.64 to
0.98) and 0.87 (0.58 to 1.29) for those aged 25-64, and
0.37(0.18to0.76)and0.06(0.01to0.58)forthoseaged
≥65. When age was modelled as a continuous variable,
the odds ratio for suicidal behaviour or ideation declined
at a rate of 2.6% per year of age (−3.9% to −1.3%,
P=0.0001) and the odds ratio for suicidal behaviour
declined at a rate of 4.6% per year of age (−7.4% to
−1.8%, P=0.001).
Conclusions Risk of suicidality associated with use of
antidepressants is strongly age dependent. Compared
with placebo, the increased risk for suicidality and
suicidal behaviour among adults under 25 approaches
that seen in children and adolescents. The net effect
seems to be neutral on suicidal behaviour but possibly
protective for suicidal ideation in adults aged 25-64 and
to reduce the risk of both suicidality and suicidal
behaviour in those aged ≥65.
INTRODUCTION
Some patients being treated for depression and other
psychiatric illnesses experience suicidal thoughts and
actions (suicidality). There is a longstanding belief that
antidepressants might have an early “activating effect”
that gives depressed patients the energy to follow
through on suicidal impulses before the mood
improvement also provided by antidepressant treat-
ment takes effect. Concern about the possibility of an
increased risk of suicide with fluoxetine led to a meet-
ing of the US Food and Drug Administration (FDA)
psychopharmacologic drugs advisory committee in
1991. The committee concluded that there was no
clear evidence of an increased risk. Labelling at that
time includeda generalstatementaboutthe riskof sui-
cide associated with depression and did not directly
suggest a causative role for antidepressants.
Overthenextdecade,additionaldatawereaccumu-
lated as applications for newer antidepressants were
reviewed and the drugs were marketed. Looking at
adult data from FDA reviews, Khan et al reported
that the risk of completed suicide was the same for
drugsandplacebo.
1Storosumetalanalysedattempted
suicides from adult data available from the medicines
evaluation board of the Netherlands and reached the
same conclusion.
2 An independent FDA analysis of
completed suicides from placebo controlled, short
term trials of antidepressants in adults also found no
drug related increase,
3 but the strength of this conclu-
sion was tempered by the low number of completed
suicides in the trials.
Analysisofdatafromseveralpaediatrictrialsonpar-
oxetine in 2003 raised a particular concern that anti-
depressant drug treatment might have led to
attempted suicide and ideation in children and adoles-
cents.TheFDAaskedallmanufacturerswhohadspon-
sored trials of antidepressants in children and
adolescents to search for reports of suicidal thinking
or behaviour during those trials and submit them to
the agency. These reports were the basis of an analysis
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mittees in 2004.
4 It showed a relative risk for suicidal
behaviourorideationof1.95(95%confidenceinterval
1.28 to 2.98) for those treated with antidepressants
compared with those given placebo. The committees
recommended that the FDA add a boxed warning to
antidepressant labelling (implemented early in 2005)
and review clinical trials of antidepressants in adults
to look for similar effects. Two previous published
meta-analyses in adults did not have access to primary
data, could not validate the identification and classifi-
cation of suicidal events, and had limited means to
establishboththeappropriatenessoftheincludedtrials
andtheinclusionofallrelevanttrials.
56Inaddition,the
outcomes considered were not comparable with those
used in the FDA study of paediatric trials. We carried
outareviewtorespondtothecommittees’requestand
address limitations of the published meta-analyses.
METHODS
Data collection
TheFDAaskedeightindustrysponsorsof12marketed
antidepressant products (bupropion, citalopram,
duloxetine, escitalopram, fluoxetine, fluoxetine/olan-
zapine(ultimatelyexcludedfrom theanalysis), fluvox-
amine, mirtazapine, nefazodone, paroxetine,
sertraline,andvenlafaxine)fordatasetsfromalldouble
blind randomised placebo controlled trials of anti-
depressant in adults for any indication.
The variables included in these datasets provided
detailed information about individual participants.
Sponsors’ dataset submissions were received by the
FDA between September 2005 and September 2006
as electronic files (in SAS transport file format).
Data were requested from completed, double blind
randomised placebo controlled trials with at least 20
participants in each treatment arm. Trials limited to
known drug responders, such as those using rando-
misedwithdrawaldesigns,werenotincluded;suchstu-
dies do not examine the effects of initiating treatment
andwouldeliminateasnon-respondersthosewhohad
shown suicidality during drug treatment.
We asked sponsors to provide a list of all known
trials, indicating which trials the sponsor planned to
include and which they intended to exclude from the
dataset and why. We then provided feedback to the
sponsors on which trials should be included in the
final dataset. Sponsors summarised the characteristics
of the trials included in the datasets in the form of two
tables: one providing the dose, duration, and number
of participants per trial, and the other providing the
trial exclusion criteria.
Other than dataset formats, instructions for identify-
ing and classifying events possibly related to suicidality
(suicidal thoughts and actions) and the event classifica-
tionprocess, we did not specifywho orhow companies
should retrieve or compile the information we
requested.Eachcompanyhasitsownsystemforarchiv-
ing and maintaining its records ofclinical studies. They
areinthebestpositiontojudgetheoptimalapproachto
completingthesetasks.Eachcompanydesignatedaper-
son to serve as the main contact with the FDA.
Adverse events in these trials were solicited by gen-
eralinquiryandrecordedincasereportforms.Follow-
ing the approach used in the paediatric study,
4
sponsors were asked to search their electronic data-
bases for adverse events reported during the double
blind phase of treatment for terms related to suicidal-
ity. Because it was difficult to determine whether
events represented a change in condition or resulted
from a pre-existing condition, all events reported dur-
ing the double blind phase were included. Events that
occurred more than a day after the randomised treat-
ment stopped were excluded.
Thedatarequestletteraskedsponsorstosearchclin-
icaltrialdatabasesforpreferredterms,verbatimterms,
and any comment fields for the following text strings:
“accident-”, “attempt”, “burn”, “cut”, “drown”, “gas”,
“gun”, “hang”, “hung”, “immolat”, “injur-”, “jump”,
“monoxide”, “mutilat-”, “overdos-”, “self damag-”,
“self harm”, “self inflict”, “self injur-”, “shoot”,
“slash”, “suic-”, “poison”, “asphyxiation”, “suffoca-
tion”, “firearm”. All events identified by this search
were considered as possibly related to suicidality,
unless they were identified as “false positive” results:
events that included any of these text strings but were
not related to suicidality. For example, “epigastric
pain” would be identified in the search for the text
string “gas.” Sponsors submitted listings of the events
they classified as “false positives,” which were
reviewed by FDA staff.
Thedatasetsincluded406clinicaltrialswith103491
participants. Six trials were duplicated in the submis-
sions. We excluded 28 other trials: 23 because at least
one trial arm contained fewer than 20 participants,
three because data at the patient level were not avail-
able, and two because the study drug was a combined
antidepressant/antipsychotic. We also excluded parti-
cipantsassignedtoa non-antidepressantactive control
drug(608), leavinga total of 372 trialswith 99231 par-
ticipants (fig 1). Most of the studies were unpublished;
those that had been published in some form seldom
contained information concerning suicidality in the
publication. None of the studies was included in the
previous study of paediatric trials.
Determination of suicidality outcomes
Sponsors prepared case narratives for each event pos-
sibly related to suicidality (suicidal thoughts and
actions). Details that might bias classification (such as
treatment assignment) were removed. Because of the
large number of participants, the sponsors and not the
FDA adjudicated events. Adjudicators, who were
blinded to treatment assignment, classified events
using the approachof Posner et al.
7 Eventswere classi-
fied into seven mutually exclusive categories: 1 com-
pleted suicide, 2 suicide attempt, 3 preparatory acts
towards imminent suicidal behaviour, 4 suicidal idea-
tion, 5 self injurious behaviour, intent unknown, 6 not
enough information (fatal), and 7 not enough
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events,wecodedonlythemostsevereevent(forexam-
ple,completedsuicidewouldbecodedratherthansui-
cide attempt if both had occurred).
Three individuals with appropriate training and
expertise independently rated events. Sponsors
engaged outside contractors experienced in the
method of Posner et al,
7 either to conduct the rating
processortotrainthesponsor’sstaff.Ifthethreeraters
were not unanimous in their ratings, a discussion
among the raters, led by a fourth rater, was conducted
with the goal of achieving consensus. If consensus was
not achieved, the event was rated as indeterminate
(category 6 or 7).
Statistical analysis
The primary outcome was defined as suicidal ideation
orworse(categories1,2,3,or4).Thiscorrespondedto
the primary outcome (definitive suicidal behaviour/
ideation) used in the FDA’s paediatric analysis of sui-
cidality. The second outcome variable, considered in
parallel with the primary outcome, was preparatory
actionsorworse(categories1,2,or3),alsocalledsuici-
dalbehaviour.Welookedatideationaloneforthesake
ofcomparisonbutdidnotconsideritaclinicallyimpor-
tantoutcomebecausethecategoryexcludesboththose
who had neither suicidal ideation nor behaviour and
those who had both. Because of the previous finding
of increased suicidality with antidepressant use in chil-
dren and adolescents, we considered findings within
the general outcomes of suicidal ideation or worse
and suicidal behaviour or worse that would be
consistent with this observation in a set order. The pri-
mary hypothesis for each outcome was that the out-
come would be increased among all adults using
antidepressants. The principal secondary hypothesis,
contingent on rejection of the primary hypothesis,
was that the subpopulation of adults most similar to
children and adolescents—that is, young adults
(defined as age <25)—would show an increased risk.
If this second hypothesis was confirmed, we would
then consider the possibility of an increased risk in the
next youngest 10 year group (age 25-34), and so forth.
We used conditional logistic regression to calculate
odds ratios and obtained risk differences with popula-
tion averaged general estimating equations. These
methods were chosen for computational speed and
ease of inclusion of covariates. The insensitivity of the
resultstothemethodwassupportedbyobtainingsimi-
lar results for the principal analyses with other techni-
ques: exact methods, Mantel-Haenszel, Bayesian, and
unconditional and random effects logistic regression.
8
Allanalyseswereconditionedorstratifiedbystudy.To
examine trial heterogeneity, we added treatment by
trial interaction terms to the model. Heterogeneity of
effect by drug and drug class was similarly modelled.
We used a random effects logistic regression model to
modelageandage-treatmentinteractionascontinuous
variables in a post hoc analysis. Analyses were per-
formed with Stata version 9.2 and SAS version 9.1.
Subgroup analyses were performedbased on demo-
graphics, characteristics at the trial level, indication,
and drug class. As we were particularly interested in
age because of the association of suicidality with anti-
depressant use in the paediatric population, we
performed analyses using age and the interaction of
age with treatment as both categorical and continuous
variables.
To obtain results that could be directly compared
withtwopublishedmeta-analysesofsuicidalityinclin-
ical trials of selective serotonin reuptake inhibitors
(SSRIs),
56we compared odds ratios for SSRI with pla-
cebo for completed suicide (outcome 1), non-fatal self
harm (outcomes 2 and 5), and suicidal ideation alone
(outcome 4), and, for SSRIs compared with tricyclics,
for any suicide attempt (outcomes 1 and 2).
We classified treatment indications into one of five
indication groups by FDA physicians: major depres-
sive disorder, other depressive disorders, other psy-
chiatric disorders, other behavioural disorders, and
non-behavioural disorders. We divided the 18 anti-
depressantdrugsusedaseitherprimarydrugsoractive
controls in adult trials into five classes: selective sero-
tonin reuptake inhibitors (SSRIs), serotonin-noradre-
naline (norepinephrine) reuptake inhibitors (SNRIs),
other modern antidepressants, tricyclic anti-
depressants, and other antidepressants.
RESULTS
Characteristics of the data
Table 1 summarises the demographic characteristics
of the study population. The total duration of
406 trials submitted by sponsors (n=103 491)
Six duplicate submissions (n=2068)
397 trials (n=101 409)
374 trials (n=100 450)
23 trials with fewer than 20 subjects
in one of the treatment arms (n=959)
400 trials (n=101 423)
Assigned to non-antidepressant active control (n=608)
372 trials (n=99 231)
77 trials for non-psychiatric indications (n=22 024)
295 trials for psychiatric indications (n=77 207)
Three trials with no patient level data on those
without adverse events related to suicidality (n=14)
372 trials (n=99 839)
Two trials of combination
antipsychotic/antidepressant (n=611)
Fig 1 | Flow diagram of exclusions of trials and participants
(numbers shown in parentheses)
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the numbers of participants by drug, drug class, and
treatment assignment. Table 3 shows the incidence
of suicidality by indication group. There were eight
reported completed suicides, 134 reported suicide
attempts,10reportsofpreparationswithoutattempted
suicide,and378reportedsuicidalideationalone—that
is, without any action. The incidence rates for suicidal-
ity in those with major depression were higher than in
the other indication groups; incidence rates for other
depressive disorders and psychiatric disorders other
than depression were about two thirds of that for
major depression. The rates for non-psychiatric disor-
ders were much lower than for psychiatric disorders
and consisted almost entirely of suicidal ideation
alone. For the psychiatric categories, the ratio of parti-
cipants with ideation only to participants who
attempted suicide was about three to one (360/133).
In the non-psychiatric categories there were 18 cases
of ideation alone but only one suicide attempt.
Estimates of risk of suicidality associated with
antidepressant treatment
Table 4 shows the estimated odds ratios and risk dif-
ferences for suicidal ideation or worse associated with
assignment to antidepressant drug treatment com-
pared with placebo. For the entire dataset, the odds
ratio was 0.85 (95% confidence interval 0.71 to 1.02).
The estimated odds ratio for preparatory acts or worse
was 1.12 (0.79 to 1.58). The odds ratio for completed
suicide (2.13) was higher for those treated with an
antidepressant, but this was based on just eight events
and was not significant (0.41 to 10.99).
Table 4 also compares risk of suicidality by indica-
tion. The psychiatric indication categories seem
remarkably similar, while the non-psychiatric cate-
gories seem similar to each other but distinct from the
psychiatriccategories.Thedifferencebetweenthepsy-
chiatric diagnoses and the non-psychiatric diagnoses,
however, was not significant (P=0.25). As there were
few events in the non-psychiatric categories, an esti-
mate combining observations across all categories
would be largely determined by the events in psychia-
tric trials; it might be misleadingly applied to people
with non-psychiatric indications. Therefore, we have
limited further analyses presented to the 77207 parti-
cipants in 295 clinical trials for psychiatric indications.
Table 5showstheoddsratiosandriskdifferencesfor
suicidality for antidepressant treatment in psychiatric
disorders by drug and drug class. For the entire popu-
lation with psychiatric disorders, there was a decrease
in suicidality with treatment. Other statistical techni-
ques showed nearly identical results. Statistical tests
for differences in effect among drugs and drug classes
had negative results, with the exception of some indi-
cationofdifferencesamongSSRIs.Therewaslittledif-
ference between older and newer drugs. The odds
ratios for suicidal behaviour were slightly higher than
those observed for suicidality.
Estimatesofheterogeneityintreatmenteffectamong
trialsandofinteractionoftreatmenteffectwithstatusof
a drug as test drug or active control, trial location, sex,
and ethnicity were all non-significant (P>0.35).
Table 1 |Demographic data for 99 231 people included in
randomised placebo controlled trials on antidepressants
Percentage*
Age (years):
Mean 43.1
Median (range) 42 (15-99)
<25 8.0
≥65 8.6
Sex:
Female 63.1
Male 36.9
Ethnicity:
White 86.9
Black 5.2
Hispanic 3.5
Asian 2.7
Other 1.6
Location:
North America 75.5
Other countries 24.5
Indication class:
Major depression 45.6
Other depression 4.6
Other psychiatric 27.6
Behavioural 13.5
Other 8.7
*Except where stated otherwise.
Table 2 |Numbers of participants by drug, drug class, and
treatment assignment
Drug Primary Active control Placebo
Selective serotonin reuptake inhibitor:
Citalopram 1928 733 1371
Escitalopram 2567 563 2604
Fluoxetine 9070 2418 7645
Fluvoxamine 2187 0 1828
Paroxetine 8728 1223 7005
Sertraline 5821 1129 5589
Duloxetine 6361 0 4172
Venlafaxine 5693 129 4054
Other modern antidepressants:
Bupropion 6018 0 3887
Mirtazapine 1268 0 726
Nefazodone 3319 0 2173
Tricyclic antidepressants:
Amitriptyline 0 625 627
Clomipramine 0 632 617
Desipramine 0 315 298
Dosulepin 0 106 95
Imipramine 0 2345 2304
Other antidepressants:
Mianserin 0 28 28
Trazodone 0 121 125
All drugs 52 960 10 367 35 904
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ality associated with assignment to antidepressant
treatment for adults with psychiatric disorders. The
most striking observation is the higher odds ratio and
riskdifferencewithantidepressanttreatmentthanwith
placebo in those aged under 25 but lower odds ratio
and risk difference in those aged 25 or older. There
might also be a further distinction between a modest
protective effect of antidepressants in people aged 25-
64andastrongerprotectiveeffectinthoseaged65and
older.Whenwemodelledageasacontinuousvariable,
the oddsratiodeclinedat a rateof2.6% peryearofage
(−3.9% to −1.3%, P=0.001).
Table 6 also shows risks by age for suicidal ideation
and suicidal behaviour. The decline in odds ratio and
risk difference with age for suicidal ideation alone was
relatively slight; the differences between major age
categories were not significant (table 7), except when
we modelled age as a continuous variable (change in
odds ratio −1.8% per year of age, −3.3% to −0.4%,
P=0.014, table 8). For suicidal behaviour, with a smal-
lernumberofevents,thedeclineinoddsratioswithage
seems steeper and the differences between age cate-
gories were more significant. When we modelled age
as a continuous variable, the odds ratio declined at a
rateof4.6%peryearofage(−7.4%to−1.8%,P=0.001).
Table 9 shows the odds ratios and risk differences for
suicidality, suicidal ideation alone, and suicidal beha-
viour broken down by age and indication category. A
pattern of increase in both odds ratio and risk differ-
ence with decreasing age is generally apparent across
all outcomes and diagnostic categories. The largest
increase in risk associated with antidepressants seems
to have been in those aged under 25 with psychiatric
disorders other than depression.
DISCUSSION
In contrast with the results of the review of paediatric
studies on suicide and antidepressants by the US Food
andDrugAdministration(FDA),
4pooledestimatesfor
the adult population did not show an increased risk of
suicidality.Whenweanalysedresultsbyage,however,
wefoundanincreasedriskamongadultsagedunder25
that approached the risk seen in children and adoles-
cents. The net effect seems moderately protective for
adults aged 25-64 and more strongly protective in
those aged 65 and older. This age related gradient
seemedsteeperforsuicidalbehaviourthanforideation
alone.
Becausetherelationbetweenantidepressantuseand
suicidality seems to be age related, the overall result is
probably a consequence of the particular age distribu-
tion of the participants in the study population. This
population was not chosen to be representative of the
age distribution of antidepressant users. If the popula-
tion had skewed younger, the overall result would
probably have shown a higher risk; if the population
had skewed older, the overall risk would probably
have been lower. The overall estimates are therefore
not generalisable.
Strengths and limitations of this study
Our study has several features not present in most
other systematic reviews. We were able to apply a uni-
form approach to the detection of possible suicide
related events across hundreds of studies and used a
validated method with proved inter-rater reliability
for classification of events.
Thisstudydiffersinimportantwaysfrommostmeta-
analyses, which rely on the published results of ana-
lyses performed in individual studies and combines
Table 3 |Incidence of suicidal behaviour or ideation by indication group. Figures are numbers (percentages) of participants
Major depression Other depression Other psychiatric Behavioural All other Total
Completed suicide 6 (0.01) 0 2 (0.01) 0 0 8 (0.01)
Attempted, not completed 90 (0.20) 7 (0.15) 36 (0.13) 1 (0.01) 0 134 (0.14)
Preparation, no attempt 7 (0.02) 1 (0.02) 2 (0.01) 0 0 10 (0.01)
Ideation alone 238 (0.53) 14 (0.30) 108 (0.39) 8 (0.06) 10 (0.12) 378 (0.38)
Total 341 (0.76) 22 (0.47) 148 (0.54) 9 (0.07) 10 (0.12) 530 (0.54)
Table 4 |Suicidality risk for active drug relative to placebo (ideation or worse) in all adults by indication
Indication category
Drug Placebo
Odds ratio (95% CI), P value Risk difference/1000 (95% CI), P value Events Participants Events Participants
All indications 326 63 327 204 35 904 0.85 (0.71 to 1.02), 0.08 −0.87 (−1.89 to 0.15), 0.10
Psychiatric indications:
All 314 50 043 197 27 164 0.83 (0.69 to 1.00), 0.05 −1.28 (−2.57 to 0.00), 0.05
Major depression 218 30 485 123 14 728 0.85 (0.67 to 1.07), 0.16 −1.42 (−3.23 to 0.40), 0.12
Other depression 13 2744 9 1863 0.90 (0.38 to 2.14), 0.81 −0.15 (−4.40 to 4.11), 0.95
Other 83 16 814 65 10 573 0.79 (0.56 to 1.11), 0.17 −1.37 (−3.33 to 0.59), 0.17
Non-psychiatric indications 12 13 284 7 8740 1.47 (0.57 to 3.79), 0.42 0.28 (−0.50 to 1.05), 0.48
Behavioural indications 6 8144 3 5218 1.43 (0.35 to 5.86), 0.62 0.16 (−0.72 to 1.03), 0.72
Other indications 6 5140 4 3522 1.51 (0.42 to 5.40), 0.53 0.38 (−0.96 to 1.73), 0.58
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trast, analysed the primary data from adverse event
reports on individual subjects to identify suicidality
events occurring within a collection of clinical trials.
(Some of the trials included in the analysis were the
basis of articles published in peer reviewed journals
but the question of suicidality was not considered in
any detail by the authors or reviewers.) We analysed
the data as primary data even though we were not
directly involved in the data collection. We believe
that our approach provided a high level of assurance
as to the completeness and accuracy of the data. Fed-
eral law requires that any research study of a drug that
has not been licensed for sale in the US and that
involves humans in the US must be reviewed in
advance by the FDA. This requirement is extended
to drugs already licensed for sale if the study in ques-
tion is intended to support commercial use, such as a
possible application for a new indication or changing
information in the drug label about safety or efficacy.
ThismeansthattheFDAhasarecordofvirtuallyevery
company supported clinical trial performedon people
in the US as well as reports of the results of those stu-
dies.Inaddition,anystudyperformedentirelyoutside
the US that provides information used in a licensing
application will also be reported. In many cases the
study reports included the original datasets and
adverse event reports. This provided us with an excel-
lent reference source with which to confirm the accu-
racy and completeness of the submissions that were
specifically requested for our study. Furthermore,
FDAstaff are expertson the clinical development pro-
grammes for these drugs and were already familiar
Table 5 |Suicidality risk for active drug relative to placebo (ideation or worse) in adults with psychiatric disorders by drug and drug class
Drug class
Drug Placebo
Odds ratio (95% CI), P value Risk difference/1000 (95% CI), P value Events Participants Events Participants
All drugs 314 50 043 197 27 164 0.83 (0.69 to 1.00), 0.05 −1.28 (−2.57 to 0.00), 0.05
Selective serotonin reuptake inhibitor:
All 205 31 440 141 21 225 0.86 (0.69 to 1.06), 0.16 −0.60 (−2.07 to 0.88), 0.43
Citalopram 24 2 661 7 1 371 2.11 (0.90 to 4.94), 0.09 4.05 (−1.38 to 9.49), 0.14
Escitalopram 10 3 130 5 2 604 2.44 (0.90 to 6.63), 0.08 1.27 (−1.38 to 3.93), 0.35
Fluoxetine 81 7 180 67 4 814 0.71 (0.52 to 0.99), 0.04 −3.39 (−7.61 to 0.82), 0.11
Fluvoxamine 22 2 187 13 1 828 1.25 (0.66 to 2.39), 0.49 3.13 (−2.80 to 9.06), 0.30
Paroxetine 50 9 919 29 6 972 0.93 (0.62 to 1.42), 0.75 0.50 (−1.56 to 2.55), 0.64
Sertraline 18 6 363 28 5 081 0.51 (0.29 to 0.91), 0.02 −2.50 (−4.99 to −0.01), 0.05
Serotonin-noradrenaline reuptake inhibitor:
All 54 7 920 48 5 364 0.81 (0.56 to 1.19), 0.28 −2.45 (−5.69 to 0.80), 0.14
Duloxetine 25 2 327 18 1 460 0.88 (0.47 to 1.63), 0.68 −2.23 (−9.11 to 4.65), 0.52
Venlafaxine 29 5 593 30 3 904 0.71 (0.44 to 1.16), 0.17 −2.55 (−6.02 to 0.92), 0.15
Other modern antidepressants:
All 27 6 511 24 4 225 0.83 (0.49 to 1.41), 0.49 −1.18 (−4.09 to 1.74), 0.43
Bupropion 7 2 659 4 1 800 1.35 (0.45 to 4.06), 0.59 −0.50 (−3.15 to 2.14), 0.71
Mirtazapine 8 1 016 6 644 0.97 (0.34 to 2.78), 0.96 −0.02 (−9.14 to 9.11), 1.00
Nefazodone 12 2 836 14 1 781 0.65 (0.30 to 1.41), 0.28 −3.38 (−8.36 to 1.61), 0.18
Tricyclic antidepressants:
All 27 4 023 39 3 941 0.71 (0.45 to 1.12), 0.14 −3.98 (−8.06 to 0.10), 0.06
Amitriptyline 0 625 1 627 0 (0 to ∞), 0.99 −1.59 (−4.72 to 1.54), 0.32
Clomipramine 5 632 12 617 0.49 (0.18 to 1.34), 0.17 −11.48 (−24.4 to 1.41), 0.08
Desipramine 1 315 2 298 0.63 (0.06 to 6.25), 0.69 −3.56 (−14.76 to 7.64), 0.53
Dosulepin 0 106 1 95 0 (0 to ∞), 0.99 −10.53 (−31.0 to 1.00), 0.32
Imipramine 21 2 345 23 2 304 0.88 (0.50 to 1.53), 0.64 −2.38 (−8.19 to 3.43), 0.42
Other antidepressants:
All 1 149 2 153 0.61 (0.06 to 5.95), 0.67 −6.58 (−29.6 to 16.4), 0.58
Mianserin 1 28 1 28 1.00 (0.06 to 16.8), 1.00 0 (−97.2 to 97.2), 1.00
Trazodone 0 121 1 125 0 (0 to ∞), 0.99 −9.03 (−23.3 to 5.27), 0.22
<25
25-34
35-44
45-54
55-64
65-74
≥ 75
25-64
≥ 25
≥ 65
All ages overall
1.62 (0.97 to 2.71)
0.76 (0.53 to 1.08)
0.78 (0.53 to 1.14)
0.94 (0.60 to 1.46)
0.62 (0.30 to 1.27)
0.53 (0.22 to 1.33)
0.22 (0.06 to 0.79)
0.79 (0.64 to 0.98)
0.74 (0.60 to 0.90)
0.37 (0.18 to 0.76)
0.83 (0.69 to 1.00)
012
Age range  Odds ratio
(95% CI)
Odds ratio
(95% CI)
Fig 2 | Odds of suicidality (ideation or worse) for active drug
relative to placebo by age in adults with psychiatric disorders
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for our study, companies submitted tables of included
and excluded studies, as well as summary descriptions
oftheincludedstudies.Theinformationinthesetables
was reviewed by FDA staff for inconsistencies with
what was known from information provided in the
past. In addition, as part of the process of cleaning the
datasets, we compared the information in the datasets
withwhatwasdescribedinthesummarytablesforcon-
sistency in terms of number of participants per arm,
demographic information, drugs used, and timing
and number of adverse events.
The main limitation of our study is its inability to
addressallthepatientsandcircumstanceswithanindi-
cation for antidepressants. Patients at highest risk for
suicide are extremely unlikely to be entered into pla-
cebo controlled trials. Moreover, most of the studies
included in this analysis involved the initial treatment
of an acute condition over eight to 10 weeks of obser-
vation. It would not be surprising if epidemiological
studies (or long term randomised trials) showed a
different picture. Patients receiving antidepressants
for maintenance of a chronic condition or prevention
of relapse, who constitute much of the population tak-
ing these drugs, might not be affected in the same way
asacutelytreatedpatients;maintenancetreatmentwith
antidepressants could, for example, reduce suicides
over the longer term. This study can also do little to
resolve whether antidepressants affect the risk of
death by suicide; even in a population of tens of thou-
sands, there was only a handful of cases.
Anotherpotentialprobleminthisstudyisthesparse-
ness of the data. Many trials had only one event or no
events at all. This can potentially cause important pro-
blems for statistical techniques, particularly when the
treatmentarmsareunbalanced.
9Ourresults,however,
were highly robust and largely unaffected by choice of
statistical technique. In particular, the most interesting
finding—the continuous reduction in risk associated
with treatment with age—has such strong significance
that it would be unlikely to have been an artefact of
problems related to sparseness of data.
Table 6 |Suicidality risk by age for active drug relative to placebo in adults with psychiatric disorders
Age range
Drug Placebo
Odds ratio (95% CI), P value Risk difference/1000 (95% CI), P value Events Participants Events Participants
Ideation or worse
<25 64 4780 21 2621 1.62 (0.97 to 2.71), 0.07 5.34 (0.61 to 10.1), 0.03
≥25 250 45 263 176 24 543 0.74 (0.60 to 0.90), 0.003 −1.96 (−3.28 to −0.64), 0.004
25-64 238 41 331 152 22 126 0.79 (0.64 to 0.98), 0.03 −1.48 (−2.84 to −0.11), 0.03
25-34 85 12 479 54 6813 0.76 (0.53 to 1.08), 0.13 −1.61 (−4.23 to 1.02), 0.23
35-44 74 14 002 48 7564 0.78 (0.53 to 1.14), 0.2 −1.33 (−3.52 to 0.86), 0.24
45-54 60 9805 34 5074 0.94 (0.60 to 1.46), 0.78 −0.64 (−3.43 to 2.15), 0.65
55-64 19 5045 16 2675 0.62 (0.30 to 1.27), 0.19 −1.94 (−5.18 to 1.30), 0.24
≥65 12 3907 24 2397 0.37 (0.18 to 0.76), 0.007 −6.34 (−10.8 to −1.91), 0.005
65-74 9 2663 12 1595 0.53 (0.22 to 1.33), 0.18 −3.87 (−8.69 to 0.95), 0.12
≥75 3 1244 12 790 0.22 (0.06 to 0.79), 0.02 −12.4 (−21.7 to −3.16), 0.01
Ideation alone
<25 32 4780 13 2621 1.19 (0.61 to 2.35), 0.61 1.71 (−1.84 to 5.26), 0.34
≥25 180 45 263 135 24 543 0.70 (0.55 to 0.88), 0.003 −1.73 (−2.86 to −0.59), 0.003
25-64 169 41 331 118 22 126 0.72 (0.56 to 0.92), 0.01 −1.53 (−2.71 to −0.35), 0.01
25-34 58 12 479 37 6813 0.73 (0.48 to 1.13), 0.16 −1.16 (−3.31 to 0.99), 0.29
35-44 53 14 002 37 7564 0.74 (0.47 to 1.16), 0.19 −1.31 (−3.20 to 0.59), 0.18
45-54 44 9805 30 5074 0.77 (0.47 to 1.25), 0.29 −1.5 (−4.05 to 1.05), 0.25
55-64 14 5045 14 2675 0.56 (0.25 to 1.27), 0.16 −2.01 (−4.90 to 0.87), 0.17
≥65 11 3907 17 2397 0.53 (0.25 to 1.16), 0.11 −3.32 (−6.86 to 0.22), 0.07
65-74 8 2663 8 1595 0.83 (0.30 to 2.28), 0.72 −1.49 (−5.36 to 2.39), 0.45
≥75 3 1244 9 790 0.29 (0.08 to 1.11), 0.07 −8.54 (−16.6 to −0.53), 0.04
Suicidal behaviour
<25 32 4780 8 2621 2.30 (1.04 to 5.09), 0.04 3.64 (0.51 to 6.77), 0.02
≥25 70 45 263 41 24 543 0.87 (0.58 to 1.29), 0.48 −0.19 (−0.84 to 0.46), 0.57
25-64 69 41 331 34 22 126 1.03 (0.68 to 1.58), 0.88 0.09 (−0.58 to 0.76), 0.8
25-34 27 12 479 17 6813 0.81 (0.43 to 1.52), 0.53 −0.36 (−1.82 to 1.10), 0.63
35-44 21 14 002 11 7564 0.89 (0.42 to 1.87), 0.75 −0.00 (−1.10 to 1.10), 1.00
45-54 16 9805 4 5074 2.29 (0.73 to 7.14), 0.15 0.84 (−0.27 to 1.96), 0.14
55-64 5 5045 2 2675 0.89 (0.17 to 4.73), 0.89 0.20 (−1.25 to 1.66), 0.78
≥65 1 3907 7 2397 0.06 (0.01 to 0.58), 0.01 −2.85 (−5.23 to −0.48), 0.02
65-74 1 2663 4 1595 0.09 (0.01 to 0.95), 0.04 −2.18 (−4.80 to 0.43), 0.10
≥75 0 1244 3 790 0 (0 to ∞), 1.00 −3.71 (−7.04 to −0.37), 0.03
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Several case-control studies have addressed the ques-
tion of a differential risk of antidepressant induced sui-
cidalityacrosstheagespectrum.Olfsonetalfoundthat
antidepressant treatment was not associated with sui-
cide attempts or suicide in severely depressed adults
requiring admission to hospital.
10 In patients aged 6-
18, however, there was a significant association with
drug treatment and both suicide attempts and com-
pleted suicide. Martinez et al found no overall differ-
enceinriskbetweenSSRIsandtricyclicsbutdidfinda
suggestionofanincreasedriskofsuicidalityinpatients
aged18andyounger.
11Juurlinketalfoundgreaterrisk
of suicide in patients treated with an SSRI compared
with patients receiving other antidepressants only in
the first month of treatment.
12 The case-control meth-
ods used in these studies is subject to confounding—
notably, differential prescribing to patients perceived
to be sicker and at greater risk of suicidal behaviour.
Apart fromthe finding ofage relatedrisk, the results
are consistent with published meta-analyses of clinical
trials of SSRIs in adults conducted by Gunnell et al
5
and Fergusson et al.
6 Despite considerable differences
intheavailabilityofdata,statisticalmethods,andevent
classification, the odds ratios were remarkably similar
to those we obtained in subsets of our data that were
most comparable with those used by these authors:
odds ratios for SSRIs compared with placebo were
0.85
5versus0.86(currentstudy)forcompletedsuicide,
1.29
5versus1.25fornon-fatalselfharm,and0.79
5ver-
sus 0.76 for suicidal ideation. For a comparison of
SSRIs with tricyclics the odds ratios for fatal or non-
fatal suicide attempts were 0.88
6 versus 1.11 (current
study).
Numerous population based studies in recent years
have compared patterns of antidepressant prescribing
and suicide rates.
13 Studies in Finland, Sweden, Hun-
gary, Australia, one study in Britain, and a Europe-
wide study showed an inverse correlation between
antidepressant use and suicide rates, but studies in
Italy, Iceland, and Denmark did not show a relation.
AstudyfromNorthernIrelandshowedaninversecor-
relation in adults over age 30 but found no relation
between antidepressant use and suicide in adults aged
20-30.
14 In England and Wales Gunnell et al found no
decrease in suicides among men aged 25-34, despite a
small increase in antidepressant prescribing, but a
large reduction in suicide rates in adults over 60 that
correlated with increased antidepressant use.
15 In the
US, Gibbons et al looked at county-level suicide rates
with adjustments for age, sex, income, and race.
16
There was no overall relation with antidepressant pre-
scribing, but the prescribing of SSRIs and other newer
antidepressantswasassociatedwithlowersuiciderates
and tricyclic prescribing wasassociated with increased
suicide rates. Grunebaum et al noted a fourfold
increase in antidepressant prescribing coincident with
an overall decrease in the suicide rate of 13.5% from
1985 to 1999.
17 Milane et al looked at fluoxetine pre-
scribing between 1988 and 2002 and observed a
decline in suicide rates since its introduction.
18 The
findings in non-US studies were generally similar.
The ecological approach taken by these studies, how-
ever, does not allow causal conclusions. For example,
increased use of SSRIs and lower suicide rates could
both be consequences of economic prosperity or
greater availability of mental health services.
Explanations and implications
Some have argued that an observed increase in suicid-
ality with drug treatment could be the result of ascer-
tainment bias: an increase in reporting of suicidality
rather than a true increase. This could occur if people
were so depressed that they could not articulate suici-
dal thoughts or report suicidal behaviour until relief
was obtained from drug treatment or if they reported
suicidal thinking or behaviour only because they also
sought medical attention for drug side effects. This
effect would need to be greater than a similar bias
that could operate in the opposite direction: people in
a placebo group who, because of lack of therapeutic
effect, sought treatment for non-suicidal symptoms
and, when examined, disclosed suicidal symptoms as
well. Our findings argue against this explanation.
Ascertainmentbiascannoteasilyexplaintheobserved
agerelatednessofthefindingsorthestrongerapparent
increase in suicidality in non-depressed psychiatric
patients in the youngest age group than in depressed
patients of the same age. It also cannot explain an
apparently greater effect on promoting the reporting
of suicidal behaviour than the reporting of suicidal
ideation.
The association of antidepressant treatment with an
increased risk of suicidality and suicidal behaviour
seemsparadoxical.Ifsuicideisaresponsetothesymp-
toms of depression, treatments proved to reduce these
symptoms ought to reduce the risk of suicide. Our
study suggests, however, that the relation between sui-
cidality, age, and antidepressant treatment is generali-
sable beyond those with major depressive disorder to
Table 7 |Comparison of age specific risks for drug effect on suicidality
Age range Ratio (95% CI) P value Riskdifference/1000(95%CI) P value
Ideation or worse
<25 v ≥25 2.05 (1.26 to 3.34) 0.004 6.19 (1.76 to 10.6) 0.006
25-64 v ≥65 2.14 (1.08 to 4.24) 0.03 3.81 (0.34 to 7.28) 0.03
Ideation alone
<25 v ≥25 1.84 (0.92 to 3.67) 0.08 2.75 (−0.61 to 6.12) 0.11
25-64 v ≥65 1.45 (0.65 to 3.27) 0.37 1.55 (−1.30 to 4.40) 0.29
Preparation or worse
<25 v ≥25 2.57 (1.07 to 6.15) 0.04 3.43 (0.51 to 6.36) 0.02
25-64 v ≥65 13.8 (1.61 to 118) 0.02 2.42 (0.47 to 4.37) 0.02
Table 8 |Change per year of age for drug effect on suicidality
Outcome Change in odds ratio (95% CI) P value
Ideation or worse −2.6% (−3.9% to −1.3%) 0.0001
Ideation alone −1.8% (−3.3% to −0.4%) 0.01
Preparation or worse −4.6% (−7.4% to −1.8%) 0.001
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support the idea that antidepressant drugs can have
two separate effects: an undesirable effect in some
patients that promotes suicidal ideation or suicidal
behaviour and a therapeutic effect in others that alle-
viates depression and reduces any suicidal sequelae
from depression. From the standpoint of clinical deci-
sion making, the age dependent increase in suicidality
would be considered a phenomenon separate from
therapeutic effect and approached like any other
uncommon but serious adverse effect. Patients whose
illnessesposelessriskofsuicidalideationorbehaviour,
such as those without major depression, could have
less potential to benefit from any effect drug treatment
might have on reducing suicidal sequelae but be little
different from patients with major depression in vul-
nerability to adverse effects.
The possibility of separate therapeutic and adverse
effectsfromantidepressantdrugsonsuicideideationor
behaviour should be the subject of further research,
particularly in terms of possible mechanisms for age
related differences. Another possible topic for investi-
gation would be differences among drugs. Although
this study did not show much evidence for differences
between antidepressant drugs in net effect on suicidal
behaviour or ideation, further investigation could
reveal whether some drugs cause relatively substantial
increases in both adverse and therapeutic effects while
other drugs have little effect on either.
When we presented these results at a meeting of
thePsychopharmacologicDrugsAdvisoryCommittee
in December 2006 [www.fda.gov/ohrms/dockets/ac/
06/briefing/2006-4272b1-01-fda.pdf], the committee
agreed with FDA’s conclusions that the risk of suicid-
ality associated with antidepressants in young adults
(under 25) approached that seen in children and ado-
lescents, that the net effect seemed to be neutral in
adults aged 25-65, and that the effect on suicidality
was favourable in adults older than 65. They
Table 9 |Suicidality risk for active drug relative to placebo by age and diagnostic category
Diagnostic category
Age <25 Age 25-64 Age ≥65
Estimate (95% CI) P value Estimate (95% CI) P value Estimate (95% CI) P value
Odds ratio
Ideation or worse:
Major depressive disorder 1.46 (0.70 to 3.07) 0.31 0.89 (0.68 to 1.16) 0.38 0.38 (0.19 to 0.79) 0.01
Other depression 1.10 (0.18 to 6.56) 0.92 0.84 (0.31 to 2.30) 0.74 No events —
Other psychiatric disorders 1.92 (0.88 to 4.20) 0.10 0.61 (0.41 to 0.89) 0.01 One event —
Ideation alone:
Major depressive disorder 1.56 (0.56 to 4.35) 0.40 0.74 (0.54 to 1.01) 0.06 0.56 (0.26 to 1.24) 0.15
Other depression One event — 1.06 (0.34 to 3.30) 0.92 No events —
Other psychiatric disorders 1.07 (0.40 to 2.81) 0.90 0.64 (0.41 to 0.99) 0.04 One event —
Preparation or worse:
Major depressive disorder 1.36 (0.47 to 3.96) 0.40 1.41 (0.83 to 2.38) 0.20 0.06 (0.01 to 0.58) 0.01
Other depression 2.07 (0.22 to 19.5) 0.52 0.32 (0.03 to 3.56) 0.35 No events —
Other psychiatric disorders 4.82 (1.08 to 21.4) 0.04 0.51 (0.22 to 1.18) 0.11 No events —
Risk difference/1000 participants
Ideation or worse:
Major depressive disorder 4.53 (−2.76 to 11.8) 0.22 −1.00 (−2.95 to 0.95) 0.32 −7.32 (−12.6 to −2.04) 0.01
Other depression 5.00 (−37.2 to 47.2) 0.82 −0.51 (−4.32 to 3.30) 0.79 No events —
Other psychiatric disorders 5.73 (−0.30 to 11.8) 0.06 −2.51 (−4.59 to −0.42) 0.02 −3.84 (−8.81 to 1.13) 0.13
Ideation alone:
Major depressive disorder 3.49 (−1.95 to 8.94) 0.21 −1.61 (−3.28 to 0.06) 0.06 −3.71 (−7.91 to 0.50) 0.08
Other depression −11.5 (−29.4 to 6.42) 0.21 0.25 (−3.09 to 3.58) 0.88 No events —
Other psychiatric disorders 0.79 (−4.00 to 5.58) 0.75 −1.82 (−3.67 to 0.03) 0.05 −3.84 (−8.81 to 1.13) 0.13
Preparation or worse:
Major depressive disorder 0.91 (−4.09 to 5.92) 0.72 0.60 (−0.41 to 1.60) 0.24 −3.41 (−6.25 to −0.57) 0.02
Other depression 19.1 (−17.0 to 55.2) 0.30 −0.76 (−2.51 to 1.00) 0.40 No events —
Other psychiatric disorders 5.11 (1.31 to 8.91) 0.01 −0.59 (−1.50 to 0.32) 0.20 No events —
WHAT IS ALREADY KNOWN ON THIS TOPIC
Clinicaltrialsofantidepressantsinchildrenandadolescentshaveshownanincreasedriskof
suicidal thoughts or behaviour relative to those who received placebo.
Epidemiological studies have tended to show an association of lower rates of suicide with
higher rates of antidepressant use
WHAT THIS STUDY ADDS
Effects on suicidal thoughts or behaviour associated with antidepressants observed in
clinical trials are strongly age dependent; risk declines and benefit increases with increasing
age
The age related gradient seems steeper for suicidal behaviour than for ideation alone
Beneficialeffectsonsuicidalthoughtsandideationweremoststronglyassociatedwitholder
people treated for major depression, whereas harmful effects were most strongly associated
with younger people treated for psychiatric disorders other than depression
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BMJ | ONLINE FIRST | bmj.com page 9 of 10recommendedthattheFDAshouldexpandthesuicid-
ality warning language in labelling and in the medica-
tion guide with this new information, including the
strong age relatedness of the findings. Because of con-
cerns of a possible negative impact of the FDA’s regu-
latory actions on appropriate treatment of depression,
especially in younger patients, the committee also
recommended that the warnings on the labelling and
in medication guides include language making clear
that depression is a serious illness that itself is a strong
predictor of suicide. These changes to labelling and
medication guides have now been implemented.
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